engMarron, S.E.Cerro-Muñoz, P.A.Palma-Ruiz, A.M.Simal-Gil, E.Garcia-Felipe, R.Porta-Aznarez, N.Martin-Marco, R.Baldellou-Lasierra, R.Gilaberte-Calzada, Y.Alcalde-Herrero, V.M.Fuentelsaz del Barrio, M.V.Garcia-Latasa de Aranibar, F.J.Alvarez-Salafranca, M.Tomas-Aragones, L.Patient reported outcomes (PROS) in psoriasis patientsART-2019-122187P20 Introduction: Psoriasis is a chronic skin disease with negative physical, mental and social manifestations. Method: We carried out a longitudinal and prospective study under routine clinical practice conditions. The objective of the study was to measure quality of life with the Short Form-36 Survey (SF-36) and correlate the results with clinical variables using the PASI and BSA in a group of 17 patients with moderate to severe psoriasis treated with Ustekinumab. Results: In the baseline evaluation we observed the following results: 35.3% reported physical malfunction, 64.7% debilitating pain, 82.3% poor health in general, 76.4% bad vitality, 88.2% social malfunction, 100% emotional malfunction and 82.3% poor mental health. At week 78 we observed the following results: 41.15% reported very good physical functioning, 76.1% no pain, 58.8% good general health, 58.8% very good vitality, 70%, 5% good social functioning, 70.5% good emotional functioning and 52.9% good mental health. Conclusion: We observed that the perception of patients with moderate-severe psoriasis regarding their health at the beginning of treatment with Ustekinumab was poor and that they experienced a significant improvement throughout the successive weeks of treatment.2019http://zaguan.unizar.es/record/98425http://zaguan.unizar.es/record/98425oai:zaguan.unizar.es:98425ACTA DERMATO-VENEREOLOGICA 99, 8 (2019), 752by-nchttp://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccess